ClinicalTrials.gg
Not yet recruitingNCT06266988Updated Feb 20, 2024

A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions

A Phase 1 interventional study of Sacubitril and Valsartan Tablets 97mg/103mg and Entresto (Sacubitril and Valsartan Tablets 97mg/103mg) in Chronic Heart Failure, sponsored by Viatris Inc.. Not yet recruiting. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-20.

Sponsored by Viatris Inc. · Phase 1, Interventional, and Health services research

From the registry’s dates

  • Primary completion was expected by Apr 2024, 2 years 7 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Primary objective is to is to evaluate the bioequivalence of two formulations

Read the detailed description

The objectives of this study is to evaluate the bioequivalence of two formulations of sacubitril/valsartan 97 mg/103 mg film coated tablets, Entresto® (Reference) and Sacubitril and Valsartan Tablets 97mg/103mg (Test), after a single oral dose administration in healthy Thai subjects under fasting conditions and secondarily to examine the pharmacokinetics and safety of sacubitril, sacubitrilat and valsartan in healthy Thai subjects under fasting conditions

02

Conditions studied

  • Chronic Heart Failure

Browse trials for

03

In context

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

This study's planned enrollment of 48 is below the median of 76 across 4,049 interventional studies indexed under Heart Failure.

Browse Heart Failure studies →

Lead sponsor

Viatris Inc. is the lead sponsor of 7 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Thai Male/Female must be 18-55 years of age, body weight >50.0 kg with (BMI) = 18.0-30.0 kg/m2, inclusive.
  2. Must be in good health as determined by medical history, vital signs (blood pressure (systolic blood pressure not lower than 100 or not over 139 mmHg, diastolic blood pressure not lower than 70 or not over 89 mmHg), body temperature, pulse rate, respiratory rate) and physical examination or showing no abnormalities in the opinion of Principal/Clinical Investigator or designated physicians
  3. Screening without clinically significant abnormalities
  4. Screening visit laboratory values of blood test including hematology (CBC with differential), FBS (Fasting Blood sugar), BUN (Blood urea Nitrogen), Cr, and liver function test ( (Aspartate transaminase), ALT (Alanine transaminase) , total and ALP (Alkaline phosphatase)) must be within the normal range or showing no clinically significant abnormalities in the opinion of Principal/Clinical Investigator or designated physicians.
  5. Urinalysis results within normal limit or showing no clinically significant abnormalities in the opinion of Principal/Clinical Investigator or designated physicians.
  6. Must have serum , anti- and anti- negative
  7. Female subject must have serum β-hCG negative.
  8. Subject willing to avoid or follow precautions while driving, operating machinery and while working on high elevations.
  9. Female subject of or male subject agrees to use an acceptable method from screening visit to the followup visit. The acceptable birth control method is defined as a barrier method of contraception (including condoms, intrauterine device and diaphragm with spermicidal agent) or total abstinence from sexual intercourse from visit 1 to the follow-up visit. Hormonal contraceptives are not acceptable.
  10. Female subject of non-childbearing potential (hysterectomy, both ovaries removed, surgically sterilized or (for at least 12 consecutive months of amenorrhea))
  11. Female subject must agree not to become pregnant for the entire participation period and must have a negative result for a urine pregnancy test performing prior to dosing at Period 1, Period 2, Period 3 and Period 4.
  12. Non-smoker (never smoked or no smoking within the previous 1 year)
  13. Subject willing to not participate in blood donations (≥500 mL) until 56 days after completion of the study (last subject visit) and willing to not participate in clinical research studies until 30 days after completion of the study (last subject visit).
  14. Refrain from using herbal medications, cannabis containing products, dietary supplements (e.g., St. John's Wort, ginkgo biloba, garlic supplements), vitamins, grapefruit or grapefruit juice, or pomelo within 14 days before the first administration of product (Day 1). Subjects must agree to refrain from these items until the last collection time-point of Period 4.
  15. Subject must have ended any systemic medications or any medications that have any impact on gastrointestinal system at least 30 days prior to Day 1 or at least 5 times of elimination half-life prior to Day 1 and agree to continue their refraining throughout the follow-up period.
  16. Subject must refrain from drinking caffeine and alcohol for at least 48 hours prior to Day 1 and agree to continue their refraining throughout the last collection time-point of Period 4.
  17. Have the ability to understand the requirements of the study and must voluntarily sign and date an , approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures

Exclusion criteria

Exclusion Criteria:

  1. Known to sacubitril or valsartan or any other similar class of drugs or its components
  2. Past medical history of renal and hepatic insufficiency
  3. Subject has a history of any illness that, in the opinion of Principal/Clinical Investigator or designated physicians, might confound the result of the study or pose an additional risk in administering product to the subject. This may include but is not limited to: a history of relevant drug or food allergies; history of cardiovascular, gastrointestinal, central nervous system disease, renal and hepatic impairment; history or presence of illness; or history of mental illness that may affect compliance with study requirements.
  4. History of hereditary or idiopathic angioedema
  5. Have a history of angioedema related to previous ACE inhibitor or ARB therapy
  6. Have history of drug abuse (in the opinion of Principal/Clinical Investigator or designated physicians, as judged by medical history) in the last 12 months
  7. Have positive result of urine drug abuse testing on opioids (Mor, MTD), cannabinoids (THC), Meth, Coc or MDMA at screening visit or before dose administration at each period
  8. Alcohol abuse or excessive use (in the opinion of Principal/Clinical Investigator or designated physicians, as judged by medical history) in the last 12 months
  9. Have positive result of alcohol breathing test at screening visit or before dose administration at each period
  10. Female subject is pregnant or breast feeding.
  11. Difficulties fasting or consuming standard meals
  12. Difficulties swallowing whole tablets
  13. Donation or loss of whole blood:

    1. ≥50 mL and ≤499 mL within 30 days prior to Day 1
    2. ≥500 mL within 56 days prior to Day 1
  14. Participation in any investigational drug study within 30 days from screening visit (from the last follow-up visit to the screening visit).
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Test Product

    Sacubitril and Valsartan Tablets 97mg/103mg to be orally administered

    Drug: Sacubitril and Valsartan Tablets 97mg/103mg

  • Active comparator
    Reference product

    Entresto® (97.2 mg sacubitril and 102.8 mg valsartan as sodium salt complex) to be orally administered

    Drug: Entresto (Sacubitril and Valsartan Tablets 97mg/103mg)

Interventions

  • DrugSacubitril and Valsartan Tablets 97mg/103mg

    Each Tablet contains 97 mg of Sacubitril and 103 mg of Valsartan

    Also known as: Sacubitril and Valsartan Tablets

  • DrugEntresto (Sacubitril and Valsartan Tablets 97mg/103mg)

    Each Tablet contains 97.2 mg sacubitril and 102.8 mg valsartan as sodium salt complex

    Also known as: Entresto

06

What researchers measure

Primary outcomes

  1. Bioequivalence based on Cmax period (using the validated Phoenix® WinNonlin® software)

    According to bioequivalence criteria, the 90% CI of the geometric mean ratio of Cmax should lie within 80.00-125.00%.

    Time frame: Upto 48 hours post-dose in each treatment

  2. Bioequivalence based on AUC period (using the validated Phoenix® WinNonlin® software)

    According to bioequivalence criteria, the 90% CI of the geometric mean ratio of AUC should lie within 80.00-125.00%.

    Time frame: Upto 48 hours post-dose in each treatment

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2024; primary completion for Apr 2024, 1 month later.

Of 77 industry-sponsored phase 1 interventional studies under Heart Failure, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 16. This study's planned 1 month is below that.

Counting every sponsor, half of 131 studies reached it within 14 months; a quarter within 4 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2024
First posted
Feb 20, 2024
StartEst.
Mar 2024
Primary completionEst.
Apr 2024
CompletionEst.
Aug 2024
Last update
Feb 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06266988
Lead sponsor
Viatris Inc.
Responsible party
Sponsor
First posted
Feb 20, 2024
Start date
Mar 2024 (estimated)
Primary completion
Apr 2024 (estimated)
Completion
Aug 2024 (estimated)
Last update
Feb 20, 2024

Study contacts

Arun Kumar, M.Pharm
Contact
akumar@viatris.com
967630054
Venkatesh Daggumati, M.Pharm
Contact
Venkatesh.Daggumati@viatris.com
7032185444
Ariya Khunvichai, Ph.D
study director · Medica Innova Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion